Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Humbert, Michael ^a,b   Rasmussen, Robert A ^a,b   Ong, Helena ^a   Kaiser, Fabian M P ^a   Hu, Shiu Lok ^c   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS DNA; VIRUS ENVELOPE PROTEIN; ANTISERUM; EPITOPE; HYBRID PROTEIN; PEPTIDE LIBRARY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLADISTICS; CONTROLLED STUDY; CROSS PRESENTATION; DNA IMMUNIZATION; EPITOPE MAPPING; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; MOUSE; NONHUMAN; PHAGE DISPLAY; PROTEIN CONFORMATION; RHESUS MONKEY; VIRUS IMMUNITY; VIRUS TRANSMISSION; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD SAMPLING; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IC 50; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; MOLECULAR GENETICS; MOLECULAR MIMICRY; SERODIAGNOSIS; SPECIES DIFFERENCE; VACCINATION; WESTERN BLOTTING;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

AMINO ACID SEQUENCE; ANIMALS; BLOOD SPECIMEN COLLECTION; BLOTTING, WESTERN; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HIV ANTIBODIES; HIV-1; IMMUNE SERA; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; SPECIES SPECIFICITY; VACCINATION;

EID: 58049213922     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003937     Document Type: Article

References (71)

1. UNAIDS (2007) AIDS epidemic update: December 2007. (www.unaids.org).
2. Rowland-Jones S (2008) A winding road towards an HIV vaccine. Eur J Immunol 38: 13-14.
3. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320: 760-764.
4. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
5. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
6. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
7. McMichael AJ (2006) HIV vaccines. Annu Rev Immunol 24: 227-255.
8. Pantophlet R, Burton DR (2006) GP120: Target for Neutralizing HIV-1 Antibodies. Annu Rev Immunol 24: 739-769.
9. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6: 200-206.
10. Conley AJ, Kessler JA II, Boots LJ, McKenna PM, Schleif WA, et al. (1996) The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 70: 6751-6758.
11. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, et al. (2003) Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 17: 301-309.
12. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, et al. (2004) Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 189: 2167-2173.
13. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, et al. (2001) Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 75: 7470-7480.
14. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018.
15. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210.
16. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347.
17. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, et al. (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9: 343-346.
18. Kramer VG, Siddappa NB, Ruprecht RM (2007) Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr HIV Res 5: 642-655.
19. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
20. Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, et al. (2004) Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies-implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 189: 71-74.
21. Kitabwalla M, Ferrantelli F, Wang T, Chalmers A, Katinger H, et al. (2003) Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retroviruses 19: 125-131.
22. Xu W, Smith-Franklin BA, Li PL, Wood C, He J, et al. (2001) Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol 4: 55-61.
23. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, et al. (2005) Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A 102: 13372-13377.
24. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, et al. (1991) An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 146: 4325-4332.
25. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, et al. (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293: 1155-1159.
26. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, et al. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79: 1252-1261.
27. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
28. Coeffier E, Clement JM, Cussac V, Khodaei-Boorane N, Jehanno M, et al. (2000) Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19: 684-693.
29. McGaughey GB, Citron M, Danzeisen RC, Freidinger RM, Garsky VM, et al. (2003) HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 42: 3214-3223.
30. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
31. Zolla-Pazner S (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4: 199-210.
32. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, et al. (2000) Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8: 1329-1339.
33. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, et al. (2006) Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 80: 8729-8738.
34. Smith GP, Pentrenko VA (1997) Phage Display. Chem Rev 97: 391-410.
35. Enshell-Seijffers D, Smelyanski L, Vardinon N, Yust I, Gershoni JM (2001) Dissection of the humoral immune response toward an immunodominant epitope of HIV: a model for the analysis of antibody diversity in HIV+ individuals. FASEB J 15: 2112-2120.
36. Felici F, Galfre G, Luzzago A, Monaci P, Nicosia A, et al. (1996) Phage-displayed peptides as tools for characterization of human sera. Methods Enzymol 267: 116-129.
37. Humbert M, Antoni S, Brill B, Landersz M, Rodes B, et al. (2007) Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur J Immunol 37: 501-515.
38. Meola A, Delmastro P, Monaci P, Luzzago A, Nicosia A, et al. (1995) Derivation of vaccines from mimotopes. Immunologic properties of human hepatitis B virus surface antigen mimotopes displayed on filamentous phage. J Immunol 154: 3162-3172.
39. Prezzi C, Nuzzo M, Meola A, Delmastro P, Galfre G, et al. (1996) Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients. J Immunol 156: 4504-4513.
40. Roccasecca R, Folgori A, Ercole BB, Puntoriero G, Lahm A, et al. (2001) Mimotopes of the hyper variable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. Mol Immunol 38: 485-492.
41. Scala G, Chen X, Liu W, Telles JN, Cohen OJ, et al. (1999) Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J Immunol 162: 6155-6161.
42. Koünigs C, Rowley MJ, Thompson P, Myers MA, Scealy M, et al. (2000) Monoclonal antibody screening of a phage-displayed random peptide library reveals mimotopes of chemokine receptor CCR5: implications for the tertiary structure of the receptor and for an N-terminal binding site for HIV-1 gp120. Eur J Immunol 30: 1162-1171.
43. Riemer AB, Forster-Waldl E, Bramswig KH, Pollak A, Zielinski CC, et al. (2006) Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur J Immunol 36: 1267-1274.
44. Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, et al. (2007) Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol 369: 696-709.
45. Zwick MB, Bonnycastle LL, Menendez A, Irving MB, Barbas CF 3rd, et al. (2001) Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J Virol 75: 6692-6699.
46. Sticht J, Humbert M, Findlow S, Bodem J, Muller B, et al. (2005) A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 12: 671-677.
47. Bublil EM, Yeger-Azuz S, Gershoni JM (2006) Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120. FASEB J 20: 1762-1774.
48. Bublil EM, Freund NT, Mayrose I, Penn O, Roitburd-Berman A, et al. (2007) Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Proteins 68: 294-304.
49. Huang J, Gutteridge A, Honda W, Kanehisa M (2006) MIMOX: a web tool for phage display based epitope mapping. BMC Bioinformatics 7: 451.
50. Mayrose I, Penn O, Erez E, Rubinstein ND, Shlomi T, et al. (2007) Pepitope: epitope mapping from affinity-selected peptides. Bioinformatics 23: 3244-3246.
51. Moreau V, Granier C, Villard S, Laune D, Molina F (2006) Discontinuous epitope prediction based on mimotope analysis. Bioinformatics 22: 1088-1095.
52. Schreiber A, Humbert M, Benz A, Dietrich U (2005) 3D-Epitope-Explorer (3DEX): Localization of conformational epitopes within three-dimensional structures of proteins. J Comput Chem 26: 879-887.
53. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028.
54. Cleveland SM, Buratti E, Jones TD, North P, Baralle F, et al. (2000) Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response. Virology 266: 66-78.
55. Humbert M, Rasmussen RA, Song R, Ong H, Sharma P, et al. (2008) SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology 5: 94.
56. Rasmussen RA, Ong H, Kittel C, Ruprecht CR, Ferrantelli F, et al. (2006) DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice. Vaccine 24: 2324-2332.
57. Sharon M, Kessler N, Levy R, Zolla-Pazner S, Gorlach M, et al. (2003) Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb) 11: 225-236.
58. Rosen O, Chill J, Sharon M, Kessler N, Mester B, et al. (2005) Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry 44: 7250-7258.
59. Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, et al. (2004) The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 78: 2394-2404.
60. Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, et al. (2006) Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J Virol 80: 6865-6872.
61. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022.
62. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, et al. (2006) Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80: 5211-5218.
63. Galfre G, Monaci P, Nicosia A, Luzzago A, Felici F, et al. (1996) Immunization with phage-displayed mimotopes. Methods Enzymol 267: 109-115.
64. Zuercher AW, Miescher SM, Vogel M, Rudolf MP, Stadler MB, et al. (2000) Oral anti-IgE immunization with epitope-displaying phage. Eur J Immunol 30: 128-135.
65. Davis D, Morein B, Akerblom L, Lovgren-Bengtsson K, van Gils ME, et al. (1997) A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen. Vaccine 15: 1661-1669.
66. Keller PM, Arnold BA, Shaw AR, Tolman RL, Van Middlesworth F, et al. (1993) Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology 193: 709-716.
67. Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, et al. (2008) Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372: 233-246.
68. Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, et al. (1997) Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol 9: 1281-1290.
69. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, et al. (2006) Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 80: 6177-6181.
70. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.
71. Siddappa NB, Song R, Kramer VG, Chenine A-L, Velu V, et al. (in press) Neutralization-sensitive R5 SHIV-2873Nip encoding env from a infant with recent HIV clade C infection. J Virol; in press.